Hypercalcemia in patients with breast cancer: a survival study.
作者信息
de Wit S, Cleton F J
机构信息
Department of Clinical Oncology, University Hospital Leiden, The Netherlands.
出版信息
J Cancer Res Clin Oncol. 1994;120(10):610-4. doi: 10.1007/BF01212816.
Abstract
In a retrospective study survival after hypercalcemia in breast cancer patients has been investigated. A group of 72 patients were treated with bisphosphonate APD [3-(amino-1,1-hydroxypropylidene)bisphosphonate] and third-generation amino-containing bisphosphonates between January 1980 and October 1992. A median survival of 4.5 months was found. In a multivariate analysis, four independent prognostic factors for survival have been found: the interval between first relapse and hypercalcemia, sites of metastases at the moment of hypercalcemia, primary treatment, and the level of serum alkaline phosphatase. Patients with a "flare" reaction on tamoxifen treatment and patients with a normal serum alkaline phosphatase level and bone metastases only had a prolonged survival. Hypercalcemia associated with visceral metastases carried a very poor prognosis. The level of serum calcium in this series of patients was no prognostic indicator for survival.
摘要
相似文献
1
Hypercalcemia in patients with breast cancer: a survival study.
J Cancer Res Clin Oncol. 1994;120(10):610-4. doi: 10.1007/BF01212816.
2
Bisphosphonates and other bone agents for breast cancer.
Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD003474. doi: 10.1002/14651858.CD003474.pub4.
3
Bisphosphonates for breast cancer.
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.
4
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
5
Bisphosphonates and other bone agents for breast cancer.
Cochrane Database Syst Rev. 2012 Feb 15(2):CD003474. doi: 10.1002/14651858.CD003474.pub3.
6
Prognosis and Phenotypes of Advanced Head and Neck Carcinoma Associated With Hypercalcemia.
Head Neck. 2025 Aug;47(8):2174-2182. doi: 10.1002/hed.28126. Epub 2025 Mar 11.
7
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
8
Bisphosphonates for breast cancer.
Cochrane Database Syst Rev. 2002(1):CD003474. doi: 10.1002/14651858.CD003474.
9
Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Cochrane Database Syst Rev. 2017 Dec 18;12(12):CD003188. doi: 10.1002/14651858.CD003188.pub4.
10
A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression.
Health Technol Assess. 2013 Sep;17(42):1-274. doi: 10.3310/hta17420.
引用本文的文献
1
Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift.
Endocr Connect. 2021 Jan;10(1):R13-R24. doi: 10.1530/EC-20-0487.
2
Inpatient management of hypercalcemia portends a poor prognosis among gynecologic oncology patients: A trigger to initiate hospice care?
Gynecol Oncol Rep. 2019 Jan 26;28:1-5. doi: 10.1016/j.gore.2019.01.005. eCollection 2019 May.
3
Malignancy-Related Hypercalcemia in Advanced Solid Tumors: Survival Outcomes.
J Glob Oncol. 2017 Dec;3(6):728-733. doi: 10.1200/JGO.2016.006890. Epub 2017 Mar 15.
4
Association of calcium sensing receptor polymorphisms at rs1801725 with circulating calcium in breast cancer patients.
BMC Cancer. 2017 Aug 2;17(1):511. doi: 10.1186/s12885-017-3502-3.
5
Hypercalcaemia and hypocalcaemia: finding the balance.
Support Care Cancer. 2017 May;25(5):1639-1649. doi: 10.1007/s00520-016-3543-1. Epub 2017 Jan 12.
6
Evaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: a 10-year cohort study.
BMC Res Notes. 2012 Jan 26;5:70. doi: 10.1186/1756-0500-5-70.
7
Flare hypercalcemia after letrozole in a patient with liver metastasis from breast cancer: a case report.
J Med Case Rep. 2011 Oct 4;5:495. doi: 10.1186/1752-1947-5-495.
8
Hypercalcemia-leukocytosis syndrome in a patient with cavitating squamous cell carcinoma of the lung.
Cases J. 2009 Jan 31;2(1):108. doi: 10.1186/1757-1626-2-108.
9
Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis.
Support Care Cancer. 2008 Apr;16(4):387-92. doi: 10.1007/s00520-007-0322-z. Epub 2007 Aug 21.
10
Emergencies of calcium homeostasis.
Rev Endocr Metab Disord. 2003 May;4(2):167-75. doi: 10.1023/a:1022994104070.
本文引用的文献
1
Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphate (APD).
Breast Cancer Res Treat. 1993;25(3):277-81. doi: 10.1007/BF00689842.
2
Medical treatment of tumor-induced hypercalcemia and tumor-induced osteolysis: challenges for future research.
Support Care Cancer. 1993 Jan;1(1):26-33. doi: 10.1007/BF00326636.
3
Palliative pamidronate treatment in patients with bone metastases from breast cancer.
J Clin Oncol. 1993 Mar;11(3):491-8. doi: 10.1200/JCO.1993.11.3.491.
4
Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia.
Lancet. 1983 Jul 30;2(8344):239-43. doi: 10.1016/s0140-6736(83)90231-3.
5
The clinical course of bone metastases from breast cancer.
Br J Cancer. 1987 Jan;55(1):61-6. doi: 10.1038/bjc.1987.13.
6
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
Br J Cancer. 1987 Oct;56(4):465-9. doi: 10.1038/bjc.1987.225.
7
Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.
Am J Med. 1987 Jun;82(6):1133-42. doi: 10.1016/0002-9343(87)90215-4.
8
Bone metastases and breast cancer.
Cancer Treat Rev. 1985 Dec;12(4):251-70. doi: 10.1016/0305-7372(85)90008-8.
9
Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
Lancet. 1985 Oct 26;2(8461):907-10. doi: 10.1016/s0140-6736(85)90848-7.
10
Hypercalcaemia in patients with disseminated breast cancer.
Acta Oncol. 1990;29(5):577-80. doi: 10.3109/02841869009090054.
Zotero 插件